Table 7.
Published reproductive and oncologic outcomes after FST of embryonal RMS of the uterine cervix.
| Study, Year [Ref] | Design | FST Patients (n) |
Age (Median, Range) |
Parity | Surgery | Adjuvant Treatment | Follow Up (Median, Range) |
Recurrence, n (%) | Death, n (%) | Total Pregnancies (n) | ART (n) |
Details |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bell, 2021 [39] | Case series | 2 | 16.5 (16–17) |
NU: 2 | Excision of cervical mass: 2 | 6 courses of VAC: 2 | NA | 0 | 0 | 0 | - | - |
| Moufarrij, 2020 [40] | Case report | 1 | 17 | NU | Excision of cervical mass | 3 courses of DOX, DTIC, CTX and VCR | 324 | 0 | 0 | 1 | - | Full-term VB |
| Buruiana, 2020 [41] | Case series | 2 | 15.5 (15–16) |
NU: 2 | Simple trachelectomy: 2 | 4 courses of NACT with VCR, IFO, dactinomycin + 5 courses of adjuvant VIA: 2 | 42 (24–60) |
0 | 0 | 0 | - | - |
| Ricciardi, 2020 [23] | Retrospective | 5 | 23 (20–37) |
NU: 4; PS: 1 | Local excision: 5 | 3 or 4 courses of DOX + IFO: 2; unknown CT: 1 No CT: 2 |
186 (23–282) |
2 (40) |
0 | 1 | 0 | Recurrence during pregnancy |
| John, 2018 [42] | Case report | 1 | 13 | NU | Local excision + LEEP after CT | 6 courses of VCR, DOX and CTX | 24 | 0 | 0 | 0 | - | - |
| May, 2018 [43] | Case report | 1 | 2 | NU | Hysteroscopic resection + Laparoscopic Radical Trachelectomy after NACT |
2 courses of NACT (VAC/VCR and irinotecan) + 14 courses of adjuvant CT (ARST0531 trial protocol) | NA | 0 | 0 | 0 | - | - |
| Bouchard-Fortier, 2016 [44] | Case series | 3 | 20 (14–21) |
NU: 3 | Radical trachelectomy: 2. hysteroscopic resection + cervical conization: 1 |
VAC alternating with VCR and irinotecan (43 W): 1; 4 courses of VAC + 4 courses of VA: 1; 6 courses of VAC (NACT): 1 | 10 (8–22) |
0 | 0 | 0 | - | - |
| Ayas, 2015 [45] | Case report | 1 | 21 | NU | Conizazion + laparoscopic PLND after pregnancy | 3 courses of DOX + IFO and MESNA (NACT) | 16 | 0 | 0 | 1 | 0 | Incidental pregnancy 7 weeks after the end of NACT. Full-term C-section |
| Strahl, 2012 [46] | Case report | 1 | 18 | NU | Tumor resection + laparoscopic PLND | 4 courses of IFO, VCR and dactinomycin | 24 | 0 | 0 | 0 | 1 | Cryoconservation of ovarian tissue |
| Dehner, 2012 [24] | Retrospective | 14 | 13 (9–32) |
NU 14 | Polipectomy + LEEP: 12; biopsy: 2 |
CT (VAC): 13; no: 1 | 24 (0–216) |
3 | 0 | NA | - | - |
| Li, 2011 [25] | Retrospective | 3 | 13 (11–15) |
NU: 3 | Abdominal radical trachelectomy: 3 | 4 courses of CTX + VCR + KSM: 2; 4 courses of BLM + DDP + VP16: 1 | NA | 0 | 0 | 0 | - | - |
| Sobiczewski, 2011 [47] | Case report | 1 | 22 | NU | Polipectomy | 6 courses of VCR and dactinomycin | 71 | 0 | 0 | 1 | 0 | Full-term VB |
ART: assisted reproductive technology; BLM: bleomycin; C-section: caesarean section; CT: chemotherapy; CTX: cyclophosphamide DDP: cisplatin; DOX: doxorubicin; DTIC: dacarbazine; FST: fertility-sparing treatment; IFO: ifosfamide; KSM: actinomycin K; LEEP: loop electrosurgical excision procedure; m: months; n: number; NA: not available; NACT: neoadjuvant chemotherapy; NU: nulliparous; PLND: pelvic lymph node dissection; PS: parous; RMS: rhabdomyosarcoma; VAC: vincristine, dactinomycin and cyclophosphamide; VB: vaginal birth; VCR: vincristine; VIA: vincristine, ifosfamide and doxorubicin; VP16: etoposide; W: weeks.